Condition
Extensive Small Cell Lung Cancer
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 3 (1)
Trial Status
Unknown2
Not Yet Recruiting1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07083375Phase 2Not Yet RecruitingPrimary
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
NCT06406673Phase 2UnknownPrimary
A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
NCT06125041Phase 2RecruitingPrimary
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
NCT04234607Phase 3UnknownPrimary
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
Showing all 4 trials